July 21, 2025

Dear Duchenne Community,

This evening, Sarepta has made the difficult decision to voluntarily and temporarily pause all U.S. shipments of ELEVIDYS effective at the end of the day tomorrow, including for ambulatory patients. This step will provide Sarepta with time to fully respond to any requests from the agency as we seek to update the label for ELEVIDYS. We believe this approach will provide a forum for a collaborative, science-driven review process with the agency.

You can read more in our statement here.

Please know that this decision was not made lightly. We know some of you were scheduled or taking steps to receive therapy. We share as much information as possible in real time with your physicians and this community. We are doing all we can to ensure the future availability of this therapy because we believe that patients and families should have choices and we hear the stories of the real difference it's making for your loved ones.

Regards,

Wendy Erler

Senior Vice President, Patient Affairs

advocacy@sarepta.com